Figure 4.

VASP exerts oncogenic effects on HCC cells by activating AKT and ERK pathways. (A) Western blot was performed to investigate the influence of VASP on AKT, ERK, JNK, MAPK, and NF-κB pathways in indicated cells. GAPDH was used as an internal control. (B-D) LO2, Hep3B, and Huh7 cells overexpressing VASP and corresponding cells in the control group were treated with MK2206 (AKT inhibitor) and U0126 (p-ERK inhibitor) for 24 h and subjected to (B) migration, (C) invasion, and (D) Western blotting.